Imodium 2 mg (20 capsules)
- $21.20
The instruction for medical use
of Imodium® medicine
the Trade name
of Imodium®
the International unlicensed
name Loperamide Dosage Form
of the Capsule of 2 mg
Structure
active agent - loperamide a hydrochloride of 2.0 mg,
excipients: lactoses monohydrate of 127.0 mg, starch of corn 40.0 mg, talc 9yu0 of mg, magnesium stearate of 2.0 mg.
structure of a gelatin capsule:
Cover: ferrous oxide yellow (E 172), indigo carmine (E 132), titan dioxide (E 171), gelatin,
Body: ferrous oxide black (E 172), indigo carmine (E 132), erythrosine (E127), the titan dioxide (E 171), gelatin
the Description
the Solid gelatin capsules (size 4) consisting of the body of dark gray color and a lid of green color. Inscriptions of white color: on a lid - Imodium, on a body of the capsule - JANSSEN.
Contents of capsules – powder of white color.
Pharmacotherapeutic group
Antidiarrheal means
the ATX A07DA03 Code
the Pharmacological
Pharmacokinetics Absorption properties of loperamide – 40%. Is exposed to intensive metabolism in the course of oxidizing N-demethylation at the first passing through a liver. Communication with proteins of blood plasma - about 95%, mainly with albumine. Elimination half-life averages 10.8 h (from 9 to 14 h). It is removed generally through the digestive tract (DT) with a stake, an insignificant part is removed with urine (in the form of the conjugated metabolites).
A pharmacodynamics
of Imodium®, contacting opiate receptors in an intestines wall, suppresses release of acetylcholine and prostaglandins, reducing thereby a vermicular movement and increasing time of passing of contents on intestines. Raises a tone of an anal sphincter, reducing thereby incontinence of stool and desires by defecation.
Indications
- acute and chronic diarrhea
- regulation of a chair at patients with ileostomy
the Route of administration and doses
Inside.
Adult, including elderly:
Acute diarrhea: an initial dose - 2 capsules (4 mg), accept further on 1 capsule (2 mg) after each act of defecation in case of a liquid chair.
Chronic diarrhea: the initial dose - 2 capsules (4 mg) a day, this dose further is usually individually adjusted so that the frequency of a chair was 1-2 times a day that is usually reached at a maintenance dose from 1 to 6 capsules in day.
Maximum daily dose. In acute and chronic diarrhea - 8 capsules
(16 mg).
At emergence of a normal chair or in the absence of a chair more than 12 h drug is cancelled.
Side effects
Often
- allergic reactions (skin rash)
- a constipation and/or an abdominal distension
- intestinal colic
Seldom
- an ischuria
Very seldom
- intestinal impassability
- pain or discomfort in a stomach
- nausea, vomiting
- a hypovolemia
- decrease in content of electrolytes
- fatigue
- drowsiness, dizziness
- dryness in a mouth
- the burning sensation or prickings of language arising right after administration of drug in the form of tablets for resorption.
Contraindications
- hypersensitivity to loperamide and/or other components of drug,
- the acute dysentery and other infections of a GIT (caused including Salmonella, Shigella and Campylobacter)
- intestinal impassability (including if necessary to avoid suppression of a vermicular movement), a divertuculosis, acute ulcer colitis or a pseudomembranous coloenteritis (the diarrhea caused by reception of antibiotics)
- the first trimester of pregnancy and the period of a lactation,
- children's age up to 18 years
With care:
in a liver failure
Medicinal interactions
it was not noted
the Special
instructions Administration of drug it is necessary to stop immediately if the constipation or an abdominal distension develops.
As treatment of diarrhea by Imodium has only symptomatic character, along with it it is necessary to apply etiotropic means, whenever possible. Patients with diarrhea, especially at children, can have a hypovolemia and decrease in content of electrolytes. In such cases of the most important the replacement therapy for completion of liquid and electrolytes is. In acute diarrhea if within 48 hours the clinical improvement is not observed, reception of Imodiuma® it is necessary to stop and exclude infectious genesis of diarrhea.
Not to apply in the diarrhea which is followed by blood impurity in a chair and high temperature.
At patients with AIDS it is necessary to stop immediately treatment at the first symptoms of an abdominal distension. In some cases at patients with AIDS with infectious colitis of both the virus, and bacterial nature at treatment by Imodium the toxic megacolon can develop. Patients with an abnormal liver function have to be under careful observation for the purpose of early detection of signs of toxic damage of central nervous system.
During treatment the observance of a diet and completion of liquid is recommended.
Pregnancy and the period of a lactation
Despite the absence of instructions on teratogenic or embriotoksichesky action, during pregnancy of Imodium® it is possible to appoint only if the expected advantage of therapy for mother exceeds potential risk for a fruit.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
during treatment needs to refrain from driving of transport and occupations potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.
Overdose
Symptoms: oppression of the central nervous system (CNS): a stupor, lacks of coordination, drowsiness, a miosis, the raised muscle tone, respiratory depression, intestinal impassability. Children are more sensitive to impacts on central nervous system.
Treatment: symptomatic
the Form of release and packing
On 6 or 20 capsules place in blister strip packaging from a film of polyvinylchloride and printing aluminum foil. 1 blister strip packaging together with the instruction for use in the state and Russian languages is put in a cardboard pack.
Not to apply a period of storage of 5 years after the term specified on packing.
To Store storage conditions at a temperature from 15 to 30 °C.
To store out of children's reach!
Prescription status
Without prescription
Janssen-Silag S.A. Producer,
France. Camille Demoulen St., TSA 91003, 92787 of Issi Le Moulinl Sedex 9, France.
Name and country of the owner of the registration certificate
of LLC Johnson & Johnson,
Russia, 121614, Moscow, Krylatskaya St., 17, building 2, ph. (495) 726-55-55
The address of the organization accepting claims from consumers on quality of products
of LLC Johnson & Johnson,
Russia, 121614, Moscow, Krylatskaya St., 17, building 2, ph. (495) 726-55-55
of Imodium® medicine
the Trade name
of Imodium®
the International unlicensed
name Loperamide Dosage Form
of the Capsule of 2 mg
Structure
active agent - loperamide a hydrochloride of 2.0 mg,
excipients: lactoses monohydrate of 127.0 mg, starch of corn 40.0 mg, talc 9yu0 of mg, magnesium stearate of 2.0 mg.
structure of a gelatin capsule:
Cover: ferrous oxide yellow (E 172), indigo carmine (E 132), titan dioxide (E 171), gelatin,
Body: ferrous oxide black (E 172), indigo carmine (E 132), erythrosine (E127), the titan dioxide (E 171), gelatin
the Description
the Solid gelatin capsules (size 4) consisting of the body of dark gray color and a lid of green color. Inscriptions of white color: on a lid - Imodium, on a body of the capsule - JANSSEN.
Contents of capsules – powder of white color.
Pharmacotherapeutic group
Antidiarrheal means
the ATX A07DA03 Code
the Pharmacological
Pharmacokinetics Absorption properties of loperamide – 40%. Is exposed to intensive metabolism in the course of oxidizing N-demethylation at the first passing through a liver. Communication with proteins of blood plasma - about 95%, mainly with albumine. Elimination half-life averages 10.8 h (from 9 to 14 h). It is removed generally through the digestive tract (DT) with a stake, an insignificant part is removed with urine (in the form of the conjugated metabolites).
A pharmacodynamics
of Imodium®, contacting opiate receptors in an intestines wall, suppresses release of acetylcholine and prostaglandins, reducing thereby a vermicular movement and increasing time of passing of contents on intestines. Raises a tone of an anal sphincter, reducing thereby incontinence of stool and desires by defecation.
Indications
- acute and chronic diarrhea
- regulation of a chair at patients with ileostomy
the Route of administration and doses
Inside.
Adult, including elderly:
Acute diarrhea: an initial dose - 2 capsules (4 mg), accept further on 1 capsule (2 mg) after each act of defecation in case of a liquid chair.
Chronic diarrhea: the initial dose - 2 capsules (4 mg) a day, this dose further is usually individually adjusted so that the frequency of a chair was 1-2 times a day that is usually reached at a maintenance dose from 1 to 6 capsules in day.
Maximum daily dose. In acute and chronic diarrhea - 8 capsules
(16 mg).
At emergence of a normal chair or in the absence of a chair more than 12 h drug is cancelled.
Side effects
Often
- allergic reactions (skin rash)
- a constipation and/or an abdominal distension
- intestinal colic
Seldom
- an ischuria
Very seldom
- intestinal impassability
- pain or discomfort in a stomach
- nausea, vomiting
- a hypovolemia
- decrease in content of electrolytes
- fatigue
- drowsiness, dizziness
- dryness in a mouth
- the burning sensation or prickings of language arising right after administration of drug in the form of tablets for resorption.
Contraindications
- hypersensitivity to loperamide and/or other components of drug,
- the acute dysentery and other infections of a GIT (caused including Salmonella, Shigella and Campylobacter)
- intestinal impassability (including if necessary to avoid suppression of a vermicular movement), a divertuculosis, acute ulcer colitis or a pseudomembranous coloenteritis (the diarrhea caused by reception of antibiotics)
- the first trimester of pregnancy and the period of a lactation,
- children's age up to 18 years
With care:
in a liver failure
Medicinal interactions
it was not noted
the Special
instructions Administration of drug it is necessary to stop immediately if the constipation or an abdominal distension develops.
As treatment of diarrhea by Imodium has only symptomatic character, along with it it is necessary to apply etiotropic means, whenever possible. Patients with diarrhea, especially at children, can have a hypovolemia and decrease in content of electrolytes. In such cases of the most important the replacement therapy for completion of liquid and electrolytes is. In acute diarrhea if within 48 hours the clinical improvement is not observed, reception of Imodiuma® it is necessary to stop and exclude infectious genesis of diarrhea.
Not to apply in the diarrhea which is followed by blood impurity in a chair and high temperature.
At patients with AIDS it is necessary to stop immediately treatment at the first symptoms of an abdominal distension. In some cases at patients with AIDS with infectious colitis of both the virus, and bacterial nature at treatment by Imodium the toxic megacolon can develop. Patients with an abnormal liver function have to be under careful observation for the purpose of early detection of signs of toxic damage of central nervous system.
During treatment the observance of a diet and completion of liquid is recommended.
Pregnancy and the period of a lactation
Despite the absence of instructions on teratogenic or embriotoksichesky action, during pregnancy of Imodium® it is possible to appoint only if the expected advantage of therapy for mother exceeds potential risk for a fruit.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
during treatment needs to refrain from driving of transport and occupations potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.
Overdose
Symptoms: oppression of the central nervous system (CNS): a stupor, lacks of coordination, drowsiness, a miosis, the raised muscle tone, respiratory depression, intestinal impassability. Children are more sensitive to impacts on central nervous system.
Treatment: symptomatic
the Form of release and packing
On 6 or 20 capsules place in blister strip packaging from a film of polyvinylchloride and printing aluminum foil. 1 blister strip packaging together with the instruction for use in the state and Russian languages is put in a cardboard pack.
Not to apply a period of storage of 5 years after the term specified on packing.
To Store storage conditions at a temperature from 15 to 30 °C.
To store out of children's reach!
Prescription status
Without prescription
Janssen-Silag S.A. Producer,
France. Camille Demoulen St., TSA 91003, 92787 of Issi Le Moulinl Sedex 9, France.
Name and country of the owner of the registration certificate
of LLC Johnson & Johnson,
Russia, 121614, Moscow, Krylatskaya St., 17, building 2, ph. (495) 726-55-55
The address of the organization accepting claims from consumers on quality of products
of LLC Johnson & Johnson,
Russia, 121614, Moscow, Krylatskaya St., 17, building 2, ph. (495) 726-55-55
Related Products
Sigma Pharmaceutical Industries for the World Medical, UK (Egypt
Choludexan (Ursodeoxycholic Acid) 300 mg, 20 capsules
$40.10